Gastrointestinal Adverse Events Of the adverse effects reported during GLP-1 RA clinical trials, gastrointestinal symptoms were the most frequent, with nausea and diarrhea very common, and vomiting, constipation, abdominal pain, and dyspepsia considered to be relatively common [97]
What the Clinical Trial Data Shows So Far Cagrilintide has been studied both as a standalone agent and in combination with semaglutide (in the CagriSema trials) and alongside tirzepatide
Nutritional issues faced by patients with intestinal stoma: a narrative review
For HRT users on oral hormones, switching to non-oral delivery is even more important with tirzepatide than with semaglutide
For example, Ozempic is typically administered once a week, while Saxenda is administered daily